Investigation into DexCom's Corporate Governance Breaches

Written by Emily J. Thompson, Senior Investment Analyst

DXCM+0.87%

Source: PRnewswire

Updated: 1h ago

0mins

Source: PRnewswire

Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, potentially impacting corporate governance and shareholder rights.
Legal Relief Options: Long-term shareholders of DexCom may seek corporate governance reforms, fund recovery, or court-approved financial awards, enhancing the company's transparency and accountability.
Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and demonstrating the company's commitment to shareholder interests.
Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees, reducing the financial burden of participation in the rights enforcement process.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like DXCM with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

DXCM

$74+Infinity%1D

Analyst Views on DXCM

Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 84.81 USD with a low forecast of 68.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

23 Analyst Rating

19 Buy

3 Hold

1 Sell

Strong Buy

Current: 73.360

Low

68.00

Averages

84.81

High

112.00

Current: 73.360

Low

68.00

Averages

84.81

High

112.00

Bernstein

Outperform

maintain

$84 -> $86

2026-01-09

Reason

Bernstein

Price Target

$84 -> $86

AI Analysis

2026-01-09

maintain

Outperform

Reason

Bernstein raised the firm's price target on DexCom to $86 from $84 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Raymond James

Strong Buy

maintain

$260

2025-12-18

Reason

Raymond James

Price Target

$260

2025-12-18

maintain

Strong Buy

Reason

Jabil's (JBL) recent stock weakness does not reflect any negative surprises, as earnings, guidance, and management commentary were in line, and claims that Jabil is losing share at Dexcom (DXCM) are incorrect and is "categorically not happening," Raymond James tells investors in a research note. Near-term headwinds include elevated interest expense, a higher FY27 tax rate, and a temporary AI-related capacity retrofit, but these are well understood by investors and expected to ease as the new North Carolina facility ramps quickly toward full production, the firm adds. Raymond James has a Strong Buy rating and $260 price target on Jabil shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DXCM

Unlock Now

About DXCM

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.